Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The global value of specialty injectable drugs in key market segments will increase to more than $90bn by 2014 due to greater patient acceptance and evolving formulation and administration options, according to the US based-Greystone Research Associates.
Subscribe to our email newsletter
Greystone managing director George Perros said that the chronic nature of diseases and conditions in these segments makes repetitive dosing necessary and thus the availability of therapies in safe and simple devices and packages remains an important element of patient acceptance.
As a group, specialty injectables will continue to grow on a unit dose basis during the forecast period, but at a lower rate as the market matures and prescription growth subsides.
Growth on a total revenue basis will be negatively impacted as patent expiry on several currently high-value-per-dose biologicals result in the introduction of competing brands and biosimilars, eroding prices and pressurising product margins.